Immuneering Corporation (IMRX)

NasdaqGM: IMRX · Real-Time Price · USD

5.06

-0.14 (-2.69%)

At close: Aug 14, 2026, 3:59 PM

5.16

+1.98%

After-hours: 7:34 PM

-2.69% (1D)

Bid	3.22
Market Cap	327.37M
Revenue (ttm)	n/a
Net Income (ttm)	-57.28M
Beta	0.37
EPS (ttm)	-0.93
PE Ratio (ttm)	n/a
Forward PE	-3.92
P/B (ttm)	1.72
P/S (ttm)	n/a
Earnings Date	Nov 11, 2026

Ask	5.52
Volume	524,219
Avg. Volume (20D)	1,524,932
Open	5.18
Previous Close	5.20
Day's Range	4.93 - 5.18
52-Week Range	3.25 - 10.08
Analyst	Strong Buy
Price Target	17.5 (245.85%)
Dividends	n/a
Ex-Dividend Date	n/a

About IMRX

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patien...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 30, 2021

Employees 57

Stock Exchange NasdaqGM

Ticker Symbol IMRX

Website https://immuneering.com

Full Company Profile

Financial Performance

In 2025, Immuneering's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -56.02M, a decrease of -8.21%.

Financial Statements

Analyst Forecast

According to 8 analyst ratings, the average rating for IMRX stock is "Strong Buy". The 12-month stock price forecast is 17.5, which is upside of 245.85% from the latest price.

Stock Forecasts

Earnings Surprise

Immuneering has released their quarterly earnings on Aug 5, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.27 misses estimates by 0.00, with 32.50% YoY growth.

Next Earnings Release

Immuneering Corporation is scheduled to release its earnings on Nov 11, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · The Fly

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

1 month ago · Zacks

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · Zacks

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.